The Aegis Reiterates Buy Rating for SCYNEXIS Inc (SCYX)

The Aegis Reiterates Buy Rating for SCYNEXIS Inc (SCYX)

Several other equities research analysts have also issued reports on SCYX. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of SCYNEXIS in a report on Wednesday, February 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 target price (down previously from $15.00) on shares of SCYNEXIS in a report on Friday, March 3rd. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of SCYNEXIS in a report on Friday, March 3rd. Guggenheim restated a “buy” rating and issued a $15.00 target price on shares of SCYNEXIS in a report on Friday, March 3rd. Finally, Zacks Investment Research upgraded shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Friday, March 17th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. SCYNEXIS has an average rating of “Buy” and a consensus target price of $10.56.

SCYNEXIS Inc (NASDAQ:SCYX)‘s stock had its “buy” rating reaffirmed by investment analysts at Aegis in a research report issued on Tuesday.

Shares of SCYNEXIS (NASDAQ SCYX) opened at 1.66 on Tuesday. The firm’s 50-day moving average price is $2.12 and its 200 day moving average price is $2.94. SCYNEXIS has a 1-year low of $1.55 and a 1-year high of $5.51. The company’s market capitalization is $42.82 million.

In related news, CEO Marco Taglietti acquired 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The stock was bought at an average price of $1.69 per share, for a total transaction of $42,250.00. Following the acquisition, the chief executive officer now directly owns 277,000 shares of the company’s stock, valued at approximately $468,130. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gonzalez David Angulo acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The shares were bought at an average price of $1.70 per share, with a total value of $25,500.00. Following the acquisition, the insider now directly owns 62,000 shares in the company, valued at $105,400. The disclosure for this purchase can be found here. Company insiders own 3.91% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in shares of SCYNEXIS by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of SCYNEXIS during the first quarter worth $154,000. Geode Capital Management LLC raised its stake in shares of SCYNEXIS by 2.5% in the first quarter. Geode Capital Management LLC now owns 131,952 shares of the company’s stock worth $364,000 after buying an additional 3,228 shares during the last quarter. KCG Holdings Inc. bought a new stake in shares of SCYNEXIS during the first quarter worth $416,000. Finally, Perceptive Advisors LLC bought a new stake in shares of SCYNEXIS during the fourth quarter worth $546,000. Institutional investors own 47.81% of the company’s stock. About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SCYX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment